Gerrit J. Schuurhuis

Early apoptosis largely accounts for functional impairment of CD34+ cells in frozen-thawed stem cell grafts.

Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia.

Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia.

Novel multiparameter flow cytometry assay using Syto16 for the simultaneous detection of early apoptosis and apoptosis-corrected P-glycoprotein function in clinical samples.

Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells.

Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis-resistant protein profile at diagnosis.

Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients.

Flow cytometric evaluation of PI3K/Akt and MAPK/ERK activation.

Phenotypical and functional characterization of freshly isolated adipose tissue-derived stem cells.

Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia.

Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma.

Positive selection for CD90 as a purging option in acute myeloid leukemia stem cell transplants.

Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia.

Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia.

Towards cure of CML: why we need to know more about CML stem cells?

Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.

Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.

A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.

Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.

Exosomes Secreted by Apoptosis-Resistant Acute Myeloid Leukemia (AML) Blasts Harbor Regulatory Network Proteins Potentially Involved in Antagonism of Apoptosis.

How to assess minimal residual disease in pediatric and adult acute myeloid leukemia?

The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia.

Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party.